Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 16Vaginal Neoplasms 3Gliosarcoma 2Glioblastoma 2Endometrial Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Ovarian Epithelial 2Vulvar Neoplasms 1Small Cell Lung Carcinoma 1Retinoblastoma 1Prostatic Neoplasms 1Precancerous Conditions 1Papillomavirus Infections 1Ovarian Neoplasms 1Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Esophageal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Adenocarcinoma 1Abdominal Malignancy 1

Interventions

Sorafenib 20Bevacizumab 7pembrolizumab 5Oxaliplatin 5Melphalan 5Leucovorin 5Irinotecan 5Nivolumab 4Ipilimumab 4Fluorouracil 4Cyclophosphamide 4Capecitabine 4fludarabine 3Sirolimus 3Radiosurgery 3Gemcitabine 3Filgrastim 3Carboplatin 3toripalimab 2spartalizumab 2regorafenib 2pazopanib 2lenvatinib 2ixabepilone 2durvalumab 2atezolizumab 2Vorinostat 2Thiotepa 2Temozolomide 2Sirtuins 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Liver Neoplasms × Brachytherapy × Clear all
NCT02893982 2021-05-18

High Dose Rate Brachyablation of Primary Liver Lesions

University of Texas Southwestern Medical Center

Phase 1 Terminated
1 enrolled
Gastrointestinal

Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡